Laboratorios Farmaceuticos ROVI Stock

Laboratorios Farmaceuticos ROVI EBIT

The EBIT of Laboratorios Farmaceuticos ROVI (ROVI.MC) as of Aug 12, 2026 is 174.90 M EUR. In the previous year, EBIT was 179.55 M EUR — a change of -2.59% (lower).

EBIT

174.90 MEUR

YoY

-2.59%

Last updated:

In 2026, Laboratorios Farmaceuticos ROVI's EBIT was 174.90 M EUR, a -2.59% increase from the 179.55 M EUR EBIT recorded in the previous year.

The Laboratorios Farmaceuticos ROVI EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M EUR)
Date
EBIT (M EUR)
Jan 1, 2023
220.25 base
Jan 1, 2024
179.55 base
Jan 1, 2025
174.90 base
Jan 1, 2026 (e)
205.76 base
Jan 1, 2027 (e)
237.72 base
Jan 1, 2028 (e)
259.05 base
Jan 1, 2029 (e)
280.33 base
Jan 1, 2030 (e)
299.11 base
YEAREBIT (M EUR)
2030 est 299.11
2029 est 280.33
2028 est 259.05
2027 est 237.72
2026 est 205.76
2025 174.90
2024 179.55
2023 220.25
2022 255.85
2021 183.35
2020 74.68
2019 42.84
2018 17.46
2017 19.01
2016 28.30
2015 21.84
2014 27.69
2013 25.47
2012 21.68
2011 18.99
2010 26.00
2009 13.90
2008 28.32
2007 18.44
2006 3.49
Access this data via the Eulerpool API

Laboratorios Farmaceuticos ROVI Revenue

Laboratorios Farmaceuticos ROVI Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
829.51 M EUR
220.25 M EUR
170.34 M EUR
Jan 1, 2024
763.75 M EUR
179.55 M EUR
136.88 M EUR
Jan 1, 2025
743.48 M EUR
174.90 M EUR
140.44 M EUR
Jan 1, 2026 (e)
771.18 M EUR
205.76 M EUR
131.54 M EUR
Jan 1, 2027 (e)
890.97 M EUR
237.72 M EUR
176.75 M EUR
Jan 1, 2028 (e)
970.89 M EUR
259.05 M EUR
215.45 M EUR
Jan 1, 2029 (e)
1.05 B EUR
280.33 M EUR
244.82 M EUR
Jan 1, 2030 (e)
1.12 B EUR
299.11 M EUR
291.31 M EUR

Laboratorios Farmaceuticos ROVI Margins

Laboratorios Farmaceuticos ROVI stock margins

The Laboratorios Farmaceuticos ROVI margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Laboratorios Farmaceuticos ROVI. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Laboratorios Farmaceuticos ROVI.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
58.27 %
26.55 %
20.53 %
Jan 1, 2024
62.63 %
23.51 %
17.92 %
Jan 1, 2025
60.75 %
23.52 %
18.89 %
Jan 1, 2026 (e)
60.75 %
26.68 %
17.06 %
Jan 1, 2027 (e)
60.75 %
26.68 %
19.84 %
Jan 1, 2028 (e)
60.75 %
26.68 %
22.19 %
Jan 1, 2029 (e)
60.75 %
26.68 %
23.30 %
Jan 1, 2030 (e)
60.75 %
26.68 %
25.99 %

Laboratorios Farmaceuticos ROVI Stock analysis

What does Laboratorios Farmaceuticos ROVI do? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Laboratorios Farmaceuticos ROVI's EBIT

Laboratorios Farmaceuticos ROVI's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Laboratorios Farmaceuticos ROVI's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Laboratorios Farmaceuticos ROVI's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Laboratorios Farmaceuticos ROVI’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

EBIT of Laboratorios Farmaceuticos ROVI is 174.90 M EUR in 2026.

EBIT of Laboratorios Farmaceuticos ROVI changed from 179.55 M EUR to 174.90 M EUR, representing a -2.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Laboratorios Farmaceuticos ROVI since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Laboratorios Farmaceuticos ROVI historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Laboratorios Farmaceuticos ROVI

All Key Metrics — Laboratorios Farmaceuticos ROVI